Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria: * Have the ability to understand the study and voluntarily sign a written ICF. * Age ≥ 18 and ≤ 75 years old, male or female. * The fertile subjects agreed to take effective contraceptive measures throughout the study period. * The subjects can communicate well with the investigators and complete the follow-up according to the protocol. Exclusion Criteria: * Live vaccine or attenuated live vaccine has been vaccinated or planned to be vaccinated within 12 weeks before randomization. * He received allergen-specific immunotherapy (desensitization therapy) within 6 months before randomization. * Major surgery is planned during the study period. * Previous history of atopic keratoconjunctivitis and corneal involvement. * Other combined skin diseases that may affect the evaluation of the study. * Confronting IL-4R α Monoclonal antibody or CM310/placebo drug or ingredient allergy.